NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 387)
Posted On: 05/05/2020 3:45:41 PM
NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Expands Oncology Franchise via Exclusive Worldwide Patent and Technology License Agreement
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it has entered into a patent and technology license agreement with The University of Texas MD Anderson Cancer Center, granting Genprex an exclusive worldwide license to a portfolio of 16 patent applications and related technology (“Licensed IP”) for the treatment of cancer using Genprex’s lead drug candidate and TUSC2 gene therapy, known as “Oncoprex” or “GEN-001,” in combination with immunotherapies. The Licensed IP covers the use of Oncoprex in combination with one or more immunotherapies for the treatment of cancer, as well as the use of chemotherapy in combination with Oncoprex and immunotherapy. Although the initial disease indication for Oncoprex is non-small cell lung cancer (“NSCLC”), the Licensed IP claims patent protection for combination use of Oncoprex in all types of cancers. Per the agreement, MD Anderson will receive an up-front license fee and annual maintenance fees, with the potential for milestone payments, sublicensing fees, and product royalties. “We are pleased to advance the intellectual property that is covered by this license agreement,” Genprex Chairman and CEO Rodney Varner stated in the news release. “We are excited to be developing two distinct therapeutic approaches to lung cancer utilizing the combination of our gene therapy with successful targeted therapies, such as Tagrisso, and immunotherapies, such as Keytruda, to potentially improve patient outcomes and increase the number of patients who may benefit from these important therapies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it has entered into a patent and technology license agreement with The University of Texas MD Anderson Cancer Center, granting Genprex an exclusive worldwide license to a portfolio of 16 patent applications and related technology (“Licensed IP”) for the treatment of cancer using Genprex’s lead drug candidate and TUSC2 gene therapy, known as “Oncoprex” or “GEN-001,” in combination with immunotherapies. The Licensed IP covers the use of Oncoprex in combination with one or more immunotherapies for the treatment of cancer, as well as the use of chemotherapy in combination with Oncoprex and immunotherapy. Although the initial disease indication for Oncoprex is non-small cell lung cancer (“NSCLC”), the Licensed IP claims patent protection for combination use of Oncoprex in all types of cancers. Per the agreement, MD Anderson will receive an up-front license fee and annual maintenance fees, with the potential for milestone payments, sublicensing fees, and product royalties. “We are pleased to advance the intellectual property that is covered by this license agreement,” Genprex Chairman and CEO Rodney Varner stated in the news release. “We are excited to be developing two distinct therapeutic approaches to lung cancer utilizing the combination of our gene therapy with successful targeted therapies, such as Tagrisso, and immunotherapies, such as Keytruda, to potentially improve patient outcomes and increase the number of patients who may benefit from these important therapies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Genprex Inc. (GNPX) Stock Research Links
Scroll down for more posts ▼